Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Dermatology Reports
Erschienen in: Current Dermatology Reports 4/2021

30.09.2021 | Hospital-Based Dermatology (L Guggina and C Nguyen, Section Editors)

Recognition and Management of Toxic Erythema of Chemotherapy for the Inpatient Dermatologist

verfasst von: Nari Lee, Lida Zheng

Erschienen in: Current Dermatology Reports | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Toxic erythema of chemotherapy is an umbrella term for several non-allergic cutaneous reactions to chemotherapeutic agents. Given the heterogenous range of presentations, we will review the differential diagnoses and treatment approaches, particularly for hospitalized patients.

Recent Findings

Early recognition, holding chemotherapy, or dose reduction and monitoring fluid balance for severely ill patients is the mainstay of treatment. Supportive care with topical steroids, emollients, and wound care have shown benefit.

Summary

Toxic erythema of chemotherapy can mimic several common eruptions seen in oncologic patients. The recognition of both clinical and pathological features by inpatient dermatologists allows for appropriate management, and dose reduction if necessary, in order for patients to continue oncologic treatment.
Literatur
1.
Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008;59(3):524–9.PubMedCrossRef
2.
Horn TD. Antineoplastic chemotherapy, sweat, and the skin. Arch Dermatol. 1997;133(7):905–6.PubMedCrossRef
3.
Jacobi U, Waibler E, Schulze P, et al. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol. 2005;16(7):1210–1.PubMedCrossRef
4.
Martschick A, Sehouli J, Patzelt A, et al. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res. 2009;29(6):2307–13.PubMed
5.
•• Hunjan MK, Nowsheen S, Ramos-Rodriguez AJ, et al. Clinical and histopathological spectrum of toxic erythema of chemotherapy in patients who have undergone allogeneic hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2019;12(1):19–25. Retrospective analysis of 40 stem cell transplant patients with suspected toxic erythema of chemotherapy. Presented a clinical spectrum and histopathological examples of toxic erythema of chemotherapy, and summarized criteria necessary for diagnosis.PubMedCrossRef
6.
Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71(4):787–94.PubMedCrossRef
7.
Burgdorf WH, Gilmore WA, Ganick RG. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med. 1982;97(1):61–2.PubMedCrossRef
8.
Chidharla A, Kanderi T, Kasi A. Chemotherapy Acral Erythema. StatPearls. Treasure Island (FL)2021.
9.
Rodríguez-Lomba E, Molina-López I, Suárez-Fernández R, Baniandrés-Rodríguez O. Periarticular thenar erythema and onycholysis syndrome: a manifestation of taxane-induced cutaneous toxicity. Actas Dermo-Sifiliográficas (English Edition). 2017;108(6):595–7.CrossRef
10.
Childress J, Lokich J. Cutaneous hand and foot toxicity associated with cancer chemotherapy. Am J Clin Oncol. 2003;26(5):435–6.PubMedCrossRef
11.
Bachmeyer C, Aractingi S. Neutrophilic eccrine hidradenitis. Clin Dermatol May-Jun. 2000;18(3):319–30.CrossRef
12.
Smith SM, Milam PB, Fabbro SK, Gru AA, Kaffenberger BH. Malignant intertrigo: a subset of toxic erythema of chemotherapy requiring recognition. JAAD Case Rep. 2016;2(6):476–81.PubMedPubMedCentralCrossRef
13.
Wolf R, Tuzun Y. Baboon syndrome and toxic erythema of chemotherapy: fold (intertriginous) dermatoses. Clin Dermatol Jul-Aug. 2015;33(4):462–5.CrossRef
14.
Prieto-Barrios M, Velasco-Tamariz V, Tous-Romero F, et al. Ara-C ears: an actual drug-induced reaction or a distinctive manifestation of a neutrophilic dermatosis? J Dtsch Dermatol Ges. 2018;16(2):214–6.PubMedCrossRef
15.
Cuellar-Barboza A, Ocampo-Candiani J, Herz-Ruelas ME. A practical approach to the diagnosis and treatment of adult erythroderma. Actas Dermosifiliogr. 2018;109(9):777–90.PubMedCrossRef
16.
Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney Int. 2017;92(1):37–46.PubMedCrossRef
17.
Gill J, Dominguez AR. Cutaneous manifestations of chemotherapeutic drugs. Current Dermatology Reports. 2016/03/01 2016;5(1):58–69.
18.
Ramachandran V, Kolli SS, Strowd LC. Review of graft-versus-host disease. Dermatol Clin. 2019;37(4):569–82.PubMedCrossRef
19.
Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008;158(3):592–6.PubMedCrossRef
20.
Mann N, King T, Murphy R. Review of primary and secondary erythromelalgia. Clin Exp Dermatol. 2019;44(5):477–82.PubMedCrossRef
21.
Sehgal VN, Jain S. Acrodermatitis enteropathica. Clin Dermatol Nov-Dec. 2000;18(6):745–8.CrossRef
22.
Hegyi J, Schwartz RA, Hegyi V. Pellagra: dermatitis, dementia, and diarrhea. Int J Dermatol. 2004;43(1):1–5.PubMedCrossRef
23.
Patel GK, Finlay AY. Staphylococcal scalded skin syndrome. Am J Clin Dermatol. 2003/03/01 2003;4(3):165–175.
24.
Villarreal-Villarreal CD, Ocampo-Candiani J, Villarreal-Martinez A. Sweet syndrome: a review and update. Actas Dermosifiliogr. 2016;107(5):369–78.PubMedCrossRef
25.
Martinez-Leborans L, Victoria-Martinez AM, Torregrosa-Calatayud JL, Alegre de Miquel V. Leukemia cutis: a report of 17 cases and a review of the literature. Actas Dermosifiliogr. Nov 2016;107(9):e65-e69.
26.
Beer J, Rosenbach M. Grover disease associated with chemotherapy: review of potential pathophysiology, current treatments, and future directions. J Drugs Dermatol. 2020;19(11):1056–64.PubMedCrossRef
27.
Gantz M, Butler D, Goldberg M, Ryu J, McCalmont T, Shinkai K. Atypical features and systemic associations in extensive cases of Grover disease: a systematic review. J Am Acad Dermatol. Nov 2017;77(5):952–957 e951.
28.
Nelson CA, Stephen S, Ashchyan HJ, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses: pathogenesis, sweet syndrome, neutrophilic eccrine hidradenitis, and Behcet disease. J Am Acad Dermatol. 2018;79(6):987–1006.PubMedCrossRef
29.
Bray FN, Simmons BJ, Wolfson AH, Nouri K. Acute and chronic cutaneous reactions to ionizing radiation therapy. Dermatol Ther (Heidelb). 2016;6(2):185–206.CrossRef
30.
31.
Ji YZ, Geng L, Qu HM, et al. Acute generalized exanthematous pustulosis induced by docetaxel. Int J Dermatol. 2011;50(6):763–5.PubMedCrossRef
32.
Chiu A, Kohler S, McGuire J, Kimball AB. Cytarabine-induced acute generalized exanthematous pustulosis. J Am Acad Dermatol. 2002;47(4):633–5.PubMedCrossRef
33.
Janniger CK, Schwartz RA, Szepietowski JC, Reich A. Intertrigo and common secondary skin infections. Am Fam Physician. 2005;72(5):833–8.PubMed
34.
•• Mowad CM, Anderson B, Scheinman P, Pootongkam S, Nedorost S, Brod B. Allergic contact dermatitis: patient diagnosis and evaluation. J Am Acad Dermatol. 2016;74(6):1029–40. Systemic review and expert consensus on management of dermatologic adverse events from cancer therapiesPubMedCrossRef
35.
Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol. Nov 2012;67(5):1025–1039.
36.
37.
Martorell-Calatayud A, Sanmartin O, Botella-Estrada R, et al. Chemotherapy-related bilateral dermatitis associated with eccrine squamous syringometaplasia: reappraisal of epidemiological, clinical, and pathological features. J Am Acad Dermatol. 2011;64(6):1092–103.PubMedCrossRef
38.
Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP. High-dose cytosine arabinoside therapy for refractory leukemia. Blood. 1983;62(2):361–9.PubMedCrossRef
39.
Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol. Aug 2014;71(2):203 e201–203 e212; quiz 215–206.
40.
Cury-Martins J, Eris APM, Abdalla CMZ, Silva GB, Moura VPT, Sanches JA. Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel. An Bras Dermatol. Mar - Apr 2020;95(2):221–237.
41.
Yoshino Y, Ohtsuka M, Kawaguchi M, et al. The wound/burn guidelines - 6: Guidelines for the management of burns. J Dermatol. 2016;43(9):989–1010.PubMedCrossRef
42.
Wasiak J, Cleland H, Campbell F. Dressings for superficial and partial thickness burns. Cochrane Database Syst Rev. Oct 8 2008(4):CD002106.
43.
Bittner EA, Shank E, Woodson L, Martyn JA. Acute and perioperative care of the burn-injured patient. Anesthesiology. 2015;122(2):448–64.PubMedCrossRef
44.
Hau P, Fabel K, Baumgart U, et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer. 2004;100(6):1199–207.PubMedCrossRef
45.
von Moos R, Thuerlimann BJ, Aapro M, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer. 2008;44(6):781–90.CrossRef
46.
von Gruenigen V, Frasure H, Fusco N, et al. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer. 2010;116(20):4735–43.CrossRef
47.
Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, Stephens R. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs. 1990;8(1):57–63.PubMedCrossRef
48.
Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res. 1998;4(6):1567–71.PubMed
49.
Macedo LT, Lima JP, dos Santos LV, Sasse AD. Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer. 2014;22(6):1585–93.PubMed
50.
Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol. 2004;94(2):320–4.PubMedCrossRef
51.
Mangili G, Petrone M, Gentile C, De Marzi P, Vigano R, Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol. 2008;108(2):332–5.PubMedCrossRef
52.
Scotte F, Tourani JM, Banu E, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol. 2005;23(19):4424–9.PubMedCrossRef
53.
Scotte F, Banu E, Medioni J, et al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer. 2008;112(7):1625–31.PubMedCrossRef
54.
Templeton AJ, Ribi K, Surber C, et al. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast. 2014;23(3):244–9.PubMedCrossRef
Metadaten
Titel
Recognition and Management of Toxic Erythema of Chemotherapy for the Inpatient Dermatologist
verfasst von
Nari Lee
Lida Zheng
Publikationsdatum
30.09.2021
Verlag
Springer US
Erschienen in
Current Dermatology Reports / Ausgabe 4/2021
Elektronische ISSN: 2162-4933
DOI
https://doi.org/10.1007/s13671-021-00344-3

Weitere Artikel der Ausgabe 4/2021

Current Dermatology Reports 4/2021 Zur Ausgabe

Contact Dermatitis (Brandon Adler and Vincent Deleo, Section editors)

Contact Dermatitis to Nail Cosmetics

Contact Dermatitis (Brandon Adler and Vincent Deleo, Section editors)

Patch Testing and Immunosuppression: a Comprehensive Review

Dermatology and its Use in Social Media (R Dellavalle and C Presley, Section Editors)

Social Media and Clinical Research in Dermatology

Hospital-Based Dermatology (L Guggina and C Nguyen, Section Editors)

Management of Infectious Emergencies for the Inpatient Dermatologist

Dermatology and its Use in Social Media (R Dellavalle and C Presley, Section Editors)

Social Media for Marketing and Business Promotion in Dermatology

Contact Dermatitis (Brandon Adler and Vincent Deleo, Section editors)

Occupational Contact Dermatitis: An Individualized Approach to the Worker with Dermatitis

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise